Kirkpatrick · Journal of clinical lipidology 2019 · scientific statement / narrative review · n=?

Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force.

Cited 383 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Expert scientific statement and narrative review synthesizing findings from existing systematic reviews and meta-analyses

PubMed 31611148 · doi:10.1016/j.jacl.2019.08.003 · record verified 2026-08-29

What was done

The National Lipid Association Nutrition and Lifestyle Task Force synthesized evidence from recent systematic reviews and meta-analyses on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets. They evaluated outcomes including body weight, lipoprotein lipids, glycemic control, other cardiometabolic risk factors, and safety concerns, especially in high-risk individuals such as those with genetic lipid disorders.

What was found

The abstract reports no numerical values. Low- and very-low-carbohydrate diets were found to be not superior to other dietary approaches for weight loss. The review noted potential benefits for appetite control, triglyceride reduction, and reduction of medication use in type 2 diabetes management. Effects on low-density lipoprotein cholesterol were mixed, with some studies showing increases. There was no clear evidence of benefit for other cardiometabolic markers, and data beyond 2 years were minimal.

Why it matters

This statement provides clinical guidance summarizing that carbohydrate restriction offers comparable weight loss to other diets while cautioning about potential adverse lipid changes.

Limits

The abstract provides no quantitative data, effect sizes, or counts of included studies. The authors highlight a paucity of long-term (>2 years) safety and efficacy data, as well as potential safety concerns for patients with underlying genetic lipid disorders.

Cited by